Latest profit margin for Mycenax Biotech: -46.81% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
Mycenax Biotech (4726.TWO) currently reports a profit margin of -46.81% as of June 2026. That compares with -68.22% in the prior-year period — up 31.4% year over year. That is below the Healthcare sector average of 17.63%. Use the charts on this page to explore Mycenax Biotech's profit margin history and peer comparisons.
Mycenax Biotech's profit margin increased from -68.22% to -46.81% — a 31.4% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Mycenax Biotech's profit margin of -46.81% is lower than the Healthcare sector average of 17.63%. That is roughly 365.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' profit margin, but Mycenax Biotech's current -46.81% should be judged against Healthcare norms (sector average: 17.63%) and against 4726.TWO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current profit margin of -46.81%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 17.63%. From there, open related valuation or income-statement pages for Mycenax Biotech, and consider following 4726.TWO for alerts when major investors trade the stock.